Piers Gaunt

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Promoting engagement in patient-initiated follow-up and self-care behaviours: acceptability of the 'ACT now & check-it-out' intervention for head and neck cancer (PETNECK2 study).

Promoting engagement in patient-initiated follow-up and self-care behaviours: acceptability of the 'ACT now & check-it-out' intervention for head and neck cancer (PETNECK2 study).

Journal: BMJ open
Published: February 27, 2026

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.

Journal: British journal of cancer
Published: May 07, 2025

Development and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012.

Development and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012.

Journal: BMJ open
Published: January 14, 2025

Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.

Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.

Journal: BMJ open
Published: August 09, 2024

Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.

Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.

Journal: BMC cancer
Published: July 18, 2024

PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.

PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.

Journal: BMC cancer
Published: March 05, 2024

CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.

CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.

Journal: Trials
Published: September 26, 2023

Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.

Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.

Journal: BMC medical research methodology
Published: July 12, 2023

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.

Journal: British journal of cancer
Published: January 26, 2023

Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.

Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 14, 2022

Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma.

Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma.

Journal: British journal of cancer
Published: February 25, 2022

Early phase clinical trials extension to guidelines for the content of statistical analysis plans.

Early phase clinical trials extension to guidelines for the content of statistical analysis plans.

Journal: BMJ (Clinical research ed.)
Published: February 08, 2022
Showing 1-12 of 22

Last Updated: 09/26/2026